Telomir Pharmaceuticals Submits IND Application for Telomir-1 Targeting Triple-Negative Breast Cancer

Telomir Pharmaceuticals has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Telomir-1, targeting advanced and metastatic triple-negative breast cancer. This submission is supported by preclinical data demonstrating tumor growth reduction and favorable tolerability, positioning the oral therapy as a potential novel approach for an aggressive cancer subtype with limited treatment options. The company's regulatory filing represents a critical step toward clinical evaluation of its epigenetic mechanism, which differs from conventional cancer therapies.

Pending FDA clearance of the IND application, Telomir Pharmaceuticals plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1's safety profile, determine optimal dosing, and assess early signs of antitumor activity. This planned clinical development follows preclinical studies showing the compound's activity in modulating intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The transition from preclinical research to human trials marks a significant milestone for the company's lead program.

Triple-negative breast cancer represents a particularly challenging form of breast cancer characterized by the absence of three common receptors that typically drive tumor growth. This biological profile makes it unresponsive to many standard breast cancer treatments, creating substantial unmet medical need and driving research into novel therapeutic approaches. Telomir-1's epigenetic mechanism represents one such innovative strategy that could potentially address limitations of existing treatments for this aggressive cancer.

The submission of the IND application enables Telomir Pharmaceuticals to advance its clinical development timeline while contributing to the broader oncology research landscape focused on difficult-to-treat cancers. The company's progress can be tracked through its newsroom at https://ibn.fm/TELO, which provides updates on development milestones. This regulatory step represents both a company achievement and a potential advancement for patients facing limited treatment options for metastatic triple-negative breast cancer.

InvestorWire, the specialized communications platform that distributed this announcement, provides wire-grade press release syndication as part of the Dynamic Brand Portfolio that delivers content to thousands of outlets and millions of social media followers. The platform's distribution capabilities ensure that developments like Telomir's IND submission reach investors, journalists, and the broader public efficiently. More information about these communication services is available at https://www.InvestorWire.com, which also hosts the platform's terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.